NeuShen Therapeutics Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $80M

  • Investors
  • 12

NeuShen Therapeutics General Information

Description

Developer of therapeutic compounds and gene-based delivery systems designed for the treatment of psychiatric and neurological disorders. The company offers small-molecule discovery and AAV-based gene therapy, thereby enabling the biopharmaceutical market to address complex central nervous system conditions through targeted mechanisms, scalable clinical development, and a dual-modality approach that supports both precision medicine and broad therapeutic applicability.

Contact Information

Website
cn.neushen.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Rooms 1002 & 1003, West Tower, Gate of Science
  • Number 1819 Zhongke Road, Pudong New Area
  • Shanghai, 201210
  • China
+86 138
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • Rooms 1002 & 1003, West Tower, Gate of Science
  • Number 1819 Zhongke Road, Pudong New Area
  • Shanghai, 201210
  • China
+86 138

NeuShen Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NeuShen Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC (Series B) 03-Sep-2026 $80M Completed Generating Revenue
3. Early Stage VC (Series A1) 28-Jan-2026 Completed Generating Revenue
2. Early Stage VC (Series A) 18-Apr-2025 $20M Completed Generating Revenue
1. Early Stage VC 29-Sep-2022 $20M $20M Completed Generating Revenue
To view NeuShen Therapeutics’s complete valuation and funding history, request access »

NeuShen Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
B Capital Group Venture Capital Minority
Legend Capital Venture Capital Minority
MPC (Beijing) Venture Capital Minority
Shanghai Guotou Pioneer Private Equity Fund Management Fund of Funds Minority
LAV (Lilly Asia Fund) Corporate Venture Capital Minority
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial

NeuShen Therapeutics FAQs

  • When was NeuShen Therapeutics founded?

    NeuShen Therapeutics was founded in 2021.

  • Where is NeuShen Therapeutics headquartered?

    NeuShen Therapeutics is headquartered in Shanghai, China.

  • What industry is NeuShen Therapeutics in?

    NeuShen Therapeutics’s primary industry is Drug Discovery.

  • Is NeuShen Therapeutics a private or public company?

    NeuShen Therapeutics is a Private company.

  • What is NeuShen Therapeutics’s current revenue?

    The current revenue for NeuShen Therapeutics is .

  • How much funding has NeuShen Therapeutics raised over time?

    NeuShen Therapeutics has raised $100M.

  • Who are NeuShen Therapeutics’s investors?

    B Capital Group, Legend Capital, MPC (Beijing), Shanghai Guotou Pioneer Private Equity Fund Management, and LAV (Lilly Asia Fund) are 5 of 12 investors who have invested in NeuShen Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process